UAE - Mubasher: Abu Dhabi is hosting the first WHO-enlisted global clinical phase III trial of Sinopharm CNBG’s inactivated vaccine to fight the coronavirus (COVID-19) outbreak.

Abu Dhabi-based G42 Healthcare has partnered with Sinopharm CNBG, the world’s sixth largest vaccine manufacturer, to begin the world's first phase III trial, according to a recent press release.

To conduct the trial, UAE health authorities have issued a permit for 15,000 volunteers, among which G42 Healthcare and Abu Dhabi Health Services (SEHA) will choose 5,000 to participate in the research.

The Department of Health Abu Dhabi and SEHA are supervising the trials, applying international guidelines stipulated by WHO and the US Food and Drug Administration (USFDA).

The trial's third phase came after the successful results of phase I and II trials carried out by Sinopharm in China.

The CEO of G42 Healthcare, Ashish Koshy, said: "Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials." 

Meanwhile, the president of Biological products at Sinopharm CNBG, Jingjin Zhu, remarked: "We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide."